Mutations that drive tumorigenesis and disease progression arise from molecular abnormalities that include gene fusions, single-nucleotide polymorphisms (SNPs), insertions/deletions (indels) and copy number variations (CNVs). Combined with the fact that driver mutations can be found in any hundreds of genes, the ability to rapidly and economically characterize mutations in a large subset of potentialgenes independent of mutation type in a clinical setting has been untenable.
Anchored Multiplex PCR (AMP) is proprietary target enrichment chemistry for next-generation sequencing (NGS) that is central to the Archer™ FusionPlex™ RNA-based sequencing assay used to detect known and novel gene fusions associated with specific cancer types. The AMP chemistry is now incorporated into the Archer VariantPlex™ assay, a DNA-based sequencing assay to detect both somatic and germline mutation, including CNVs, SNPs, and indels.
In this Webinar, Josh Stahl, Vice-President of R&D and Scientific Operations, discusses:
Josh was born and raised in Baltimore, MD and studied biochemistry and molecular biology at West Virginia University. After graduation, he was drawn to Colorado by the snow and mountains. He went to graduate school at the University of Colorado Boulder, where he studied small-molecular perturbation of the TLDR4/MD-2 protein interaction and its effect on morphine analgesia.
After school, he joined Thermo Fisher Scientific, developing gene modulation tools including sequencing-based, high throughput shRNA screening techniques. He joined ArcherDX when the company was in its infancy, specifically to be part of something that would make a lasting impact on healthcare. Josh enjoys skiing, off-roading, mountain biking and playing with his dog Skye.
2477 55th Street, Suite 202
Boulder, CO 80301